Appenheimer Michelle M, Tisdale Arwen A, Fisher Daniel T, Yu Han, Repasky Elizabeth A, Evans Sharon S
Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Int J Hyperthermia. 2025 Dec;42(1):2526118. doi: 10.1080/02656736.2025.2526118. Epub 2025 Jul 9.
Murine preclinical studies established that hyperthermia regimens stimulate immunity by mobilizing lymphocyte homing to lymph nodes and tumors. Enhanced lymphocyte trafficking during fever-range systemic thermal therapy (FR-STT) is driven by interleukin-6 (IL-6) upregulation of intercellular adhesion molecule-1 (ICAM-1) on blood vessels in lymph nodes and tumors. However, since hyperthermia regulation of lymphocyte homing was only evaluated in female mice, the response of male mice remains unknown. Here, we investigated the potential sex bias in response to FR-STT by assessing the function of lymph node high endothelial venules (HEV) that are a thermally-responsive vascular site. Although it was feasible to elevate core temperatures to 39.5 ± 0.5 °C for 6 h in female and male mice, males were significantly less tolerant to FR-STT. Under normothermic controls, there was no difference between females and males in baseline intranodal (a) HEV frequency, (b) HEV area, (c) IL-6 concentration, and (d) lymphocyte trafficking. FR-STT further induced similar increases in ICAM-1 expression on HEV and lymphocyte trafficking in lymph nodes in both sexes. While FR-STT did not alter intranodal IL-6 concentrations, findings that IL-6 was higher in lymph nodes than the circulation in both sexes suggest that local IL-6 is responsible for systemic vascular responses to FR-STT. Collectively, these data demonstrate that despite sexual dimorphism in thermal regulation in mice, there was no evidence of a sex bias for lymphocyte homing at checkpoint HEV. Thus, hyperthermia treatment is predicted to be equally effective in boosting immunity in male and female mice when combined with immunotherapy.
小鼠临床前研究表明,热疗方案通过动员淋巴细胞归巢至淋巴结和肿瘤来刺激免疫。发热范围全身热疗(FR-STT)期间淋巴细胞运输增强是由白细胞介素-6(IL-6)上调淋巴结和肿瘤血管上的细胞间黏附分子-1(ICAM-1)驱动的。然而,由于仅在雌性小鼠中评估了热疗对淋巴细胞归巢的调节作用,雄性小鼠的反应仍不清楚。在此,我们通过评估作为热反应性血管部位的淋巴结高内皮微静脉(HEV)的功能,研究了对FR-STT反应中潜在的性别差异。尽管在雌性和雄性小鼠中将核心体温升高至39.5±0.5°C并持续6小时是可行的,但雄性对FR-STT的耐受性明显较低。在正常体温对照下,雌性和雄性在基线时的(a)结内HEV频率、(b)HEV面积、(c)IL-6浓度和(d)淋巴细胞运输方面没有差异。FR-STT进一步诱导两性HEV上ICAM-1表达和淋巴结中淋巴细胞运输出现类似增加。虽然FR-STT没有改变结内IL-6浓度,但两性淋巴结中IL-6高于循环中的结果表明,局部IL-6负责对FR-STT的全身血管反应。总体而言,这些数据表明,尽管小鼠在体温调节方面存在性别差异,但在检查点HEV处淋巴细胞归巢没有性别差异的证据。因此,预计热疗与免疫疗法联合使用时,在增强雄性和雌性小鼠免疫力方面同样有效。